.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Chinese Patent Office
Harvard Business School
Cantor Fitzgerald
McKesson
Cipla
Colorcon
Fuji
Deloitte
AstraZeneca

Generated: December 18, 2017

DrugPatentWatch Database Preview

Mexiletine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for mexiletine hydrochloride and what is the scope of mexiletine hydrochloride freedom to operate?

Mexiletine hydrochloride
is the generic ingredient in two branded drugs marketed by Idt Australia Ltd, Teva, Watson Labs, and Boehringer Ingelheim, and is included in five NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for mexiletine hydrochloride. Five suppliers are listed for this compound.

Pharmacology for mexiletine hydrochloride

Drug ClassAntiarrhythmic

Medical Subject Heading (MeSH) Categories for mexiletine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson LabsMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074865-002Apr 13, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Idt Australia LtdMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074450-003May 16, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
TevaMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074377-001May 16, 1995RXNoNo► Subscribe► Subscribe► Subscribe
Boehringer IngelheimMEXITILmexiletine hydrochlorideCAPSULE;ORAL018873-004Dec 30, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074711-003Feb 26, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074865-003Apr 13, 1998DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074711-002Feb 26, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
TevaMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074377-003May 16, 1995RXNoYes► Subscribe► Subscribe► Subscribe
Idt Australia LtdMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074450-002May 16, 1996DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson LabsMEXILETINE HYDROCHLORIDEmexiletine hydrochlorideCAPSULE;ORAL074711-001Feb 26, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: mexiletine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer IngelheimMEXITILmexiletine hydrochlorideCAPSULE;ORAL018873-004Dec 30, 1985► Subscribe► Subscribe
Boehringer IngelheimMEXITILmexiletine hydrochlorideCAPSULE;ORAL018873-002Dec 30, 1985► Subscribe► Subscribe
Boehringer IngelheimMEXITILmexiletine hydrochlorideCAPSULE;ORAL018873-004Dec 30, 1985► Subscribe► Subscribe
Boehringer IngelheimMEXITILmexiletine hydrochlorideCAPSULE;ORAL018873-003Dec 30, 1985► Subscribe► Subscribe
Boehringer IngelheimMEXITILmexiletine hydrochlorideCAPSULE;ORAL018873-003Dec 30, 1985► Subscribe► Subscribe
Boehringer IngelheimMEXITILmexiletine hydrochlorideCAPSULE;ORAL018873-002Dec 30, 1985► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Covington
Merck
Colorcon
Daiichi Sankyo
Accenture
Cantor Fitzgerald
Federal Trade Commission
Citi
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot